In this week's Peer Review: Teva is on the hunt for a new R&D head, and Summit's FDA rejection came after its commercial chief's exit. https://t.co/MmOWB7YYhk
After a rocky third quarter, Novartis touted a mid-stage eczema win and said it's working to restart trials of its autoimmune CAR-T. https://t.co/SjDUm5fFnC
The FDA approved Regeneron's Livsayis for myasthenia gravis, marking its entry into neurology and the second new drug for the disease in a week. https://t.co/VWQaOswKTz
Sanofi is considering a deal to buy Insmed, according to Bloomberg, in what would be one of the biggest biopharma takeovers in years. https://t.co/WpodsZ8sub
AbbVie will pay Disco $40M upfront in a deal worth up to $2.54B to find solid tumor targets for its ADC and T cell engager programs. https://t.co/LwRvAc7F2w
An @endpts exclusive: Inside Heidi Overton's failed FDA nomination, and the new, powerful White House-MAHA alliance that tanked it.
https://t.co/2pDm2yycFT
The White House pulled Heidi Overton's nomination to lead the FDA, leaving only weeks to find a replacement before Democrats take the Senate. https://t.co/runLgxP3ll
Pfizer will pay $330M upfront to Chinese biotech Starna Therapeutics for in vivo CAR-T assets, marking its entry into the space. https://t.co/YzziCw3BpE
Isomorphic's $5B Series C is the largest private raise in biotech history, though the Google-backed AI biotech has yet to reach the clinic. https://t.co/lgRG8lUndY